Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 6NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 9Thyroid Neoplasms 3Thyroid Cancer, Papillary 3Carcinoma, Medullary 3Carcinoid Tumor 3Adrenocortical Carcinoma 3Adenocarcinoma, Follicular 3Pheochromocytoma 2Paraganglioma 2Carcinoma, Renal Cell 2Carcinoma, Neuroendocrine 2Adenoma, Islet Cell 2Wilms Tumor 1Thyroid cancer, medullary 1Thyroid cancer, follicular 1Thyroid Diseases 1Thyroid Carcinoma, Anaplastic 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Rhabdomyosarcoma 1Paraganglioma, Extra-Adrenal 1Osteosarcoma 1Non functioning pancreatic endocrine tumor 1Neoplasm Metastasis 1Metastatic Digestive System Neuroendocrine Tumor G1 1High Grade Neuroendocrine Neoplasms 1Hepatoblastoma 1

Interventions

cabozantinib 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Clear-cell metastatic renal cell carcinoma × cabozantinib × Endocrine × Clear all
NCT05263050 2026-05-22

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

Fox Chase Cancer Center

Phase 2 Recruiting
111 enrolled
EndocrineGenitourinaryNET

Clear-cell metastatic renal cell carcinoma, Carcinoid Tumor, Carcinoma, Renal Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡